Here's How D-Wave Quantum's Profitability Remains Under Pressure

D-Wave's system sales fell to $0.3 million in the first half of 2026 from $13.7 million a year earlier, while Q2 operating expenses surged 93% year over year as the company continues to fund commercialization and its long-term quantum roadmap. Management expects most 2026 revenue in Q4, contingent on acceptance of two annealing systems; installation or calibration delays could shift revenue into 2027. Recurring QCaaS revenue remains insufficient to offset volatile system sales, while QBTS trades at an elevated 88.18x forward sales versus a 4.16x industry average and carries a Zacks Rank #4 (Sell).

Analysis

QBTS is effectively a lumpy hardware-delivery story being valued as a scalable software platform. That mismatch leaves the equity unusually exposed to a single acceptance-cycle disruption: a modest slip in year-end commissioning would not merely move revenue between quarters, but would challenge the market's implicit conversion assumptions and likely compress an already extreme sales multiple. Elevated fixed operating costs mean incremental revenue deferral has disproportionate cash-burn and dilution implications over the next 2-4 quarters.

The more important competitive read-through is that the public quantum cohort remains capacity- and milestone-constrained rather than demand-pull recurring-revenue businesses. IONQ's contracted pipeline offers relatively better visibility than QBTS, but remaining performance obligations are not equivalent to near-term revenue or cash collection; investors should monitor conversion, cancellations and gross-margin terms. RGTI's customer concentration creates the highest idiosyncratic downside if a single procurement program pauses, while its smaller revenue base makes a large percentage-growth narrative easier to sustain.

Near term, fourth-quarter acceptance milestones are binary catalysts for QBTS and likely raise implied-volatility sensitivity rather than justify directional exposure before confirmation. Over 6-18 months, the key structural risk is financing: sustained R&D intensity without a material rise in recurring commercial usage forces equity issuance, converts, or strategic capital, each limiting upside from technology progress. Consensus may underappreciate that technical roadmap milestones can improve sentiment without improving unit economics; the relevant proof point is recurring revenue growth and gross-margin expansion, not bookings or backlog alone.

Key Decisions for Investors

• Maintain a bearish bias on QBTS into its fourth-quarter results; use a 3-6 month put spread rather than an outright short given retail-driven squeeze risk. A practical structure is long an at-the-money put / short a 25-35% lower-strike put, sized for a 2:1 or better payoff; exit if accepted-system revenue is recognized on schedule and management demonstrates recurring-revenue acceleration with no increase in cash-burn guidance.
• For relative-value exposure, short QBTS versus long IONQ in equal dollar amounts over a 1-3 month horizon. The thesis is relative revenue visibility and lower dependence on a small number of year-end acceptance events; invalidate if IONQ's next reported RPO conversion, bookings quality, or system-delivery schedule deteriorates materially.
• Avoid long RGTI solely on quarterly growth until customer concentration declines or management identifies repeatable non-milestone revenue. Treat any loss, deferral, or non-renewal from a major customer as a short-alert catalyst, since the revenue impact would likely exceed the company's current operating-cost flexibility.
• Set a sector risk trigger around financing announcements, rising share counts, or revised cash-runway disclosures across QBTS, IONQ and RGTI. A broad capital raise would be negative for individual equity holders but may create a basket-short opportunity if valuations remain disconnected from recurring revenue growth.